Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001235817 | SCV001408522 | pathogenic | Familial aplasia of the vermis; Meckel-Gruber syndrome; Nephronophthisis | 2024-01-12 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Glu1839Lysfs*11) in the CEP290 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CEP290 are known to be pathogenic (PMID: 16909394, 17345604, 20690115). This variant is present in population databases (rs281865187, gnomAD 0.007%). This premature translational stop signal has been observed in individual(s) with Joubert syndrome (PMID: 16682973). ClinVar contains an entry for this variant (Variation ID: 99859). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003467015 | SCV004216719 | pathogenic | Bardet-Biedl syndrome 14 | 2023-01-05 | criteria provided, single submitter | clinical testing | |
Retina International | RCV000086296 | SCV000118442 | not provided | not provided | no assertion provided | not provided | ||
Natera, |
RCV001826775 | SCV002094184 | pathogenic | Leber congenital amaurosis | 2020-10-27 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004732680 | SCV005360894 | pathogenic | CEP290-related disorder | 2024-04-26 | no assertion criteria provided | clinical testing | The CEP290 c.5515_5518delGAGA variant is predicted to result in a frameshift and premature protein termination (p.Glu1839Lysfs*11). This variant was reported in individuals with Joubert syndrome (Sayer et al. 2006. PubMed ID: 16682973; Chaki et al. 2011. PubMed ID: 21866095). This variant is reported in 0.0056% of alleles in individuals of East Asian descent in gnomAD. Frameshift variants in CEP290 are expected to be pathogenic. This variant is interpreted as pathogenic. |